HIZENTRA(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

First and only subcutaneous immunoglobulin (SCIg) approved for maintenance therapy in CIDP qualifies for marketing exclusivity KING OF PRUSSIA, Pa., Dec. 9, 2019 -- (Healthcare Sales & Marketing Network) -- Global biotherapeutics leader CSL Behring ann... Biopharmaceuticals, Neurology, FDA CSL Behring, HIZENTRA, Immune Globulin, Demyelinating Polyn

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2045583

Source: HSMN NewsFeed - December 9, 2019 Category: Pharmaceuticals Source Type: news